

Human Anti-Human TNFRSF10B (tigatuzumab biosimilar) Monoclonal antibody, clone tigatuzumab (CABT-CS378)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	TNFRSF10B
Target	TNFRSF10B
Isotype	IgG1
Source/Host	Humanized
Species Reactivity	Human
Clone	tigatuzumab
Purification	Purified from cell culture supernatant by affinity chromatography
Conjugate	unconjugated
Applications	ELISA
Reconstitution	Reconstitute with deionized water
Format	Powder
Size	50 µg, 100 µg
Buffer	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.
Preservative	0.1% Procline 300

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221

Storage	Store at -20°C (Avoid repeated freezing and thawing)

BACKGROUND

Introduction	DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.
Keywords	TNFRSF10B; TRAILR2; TRAIL-R2; CD262; DR5; KILLER; TRICK2; ZTNFR9; TRICKB

GENE INFORMATION

Entrez Gene ID	8795

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221